ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides

ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides on ScienceDirect(Opens new window)
Paperback
Published: APR-2005
ISBN 10: 0-08-044560-8
ISBN 13: 978-0-08-044560-1
Imprint: ELSEVIER


By
. ICRP

Description
After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to others, but this is rarely the case after diagnostic procedures. Iodine-131 results in the most dose to medical staff, public, caregivers, and family members. Other radionuclides used in therapy are usually simple beta emitters (e.g. 32P, 89Sr, 90Y) that pose much less hazard. Dose limits apply to the exposure of the public and medical staff from patients. Prior ICRP recommendations are that no dose limit but a source-related dose constraint for optimisation of a few mSv per episode applies to the family, visitors, and caregivers at home. Here, it is recommended that young children and infants, as well as visitors not engaged in direct care or comforting, be treated as members of the public (i.e., be subject to the public dose limit).

Included in series
International Commission on Radiological Protection


 
Last update: 14 Jan 2012